Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | FAAH | O00519 | 5/20 | 0.33 |
| ▸ | REN | P00797 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA4 | P22748 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4285094 | 0.84 | SMN1; SMN2 (0.35) | RENCA1CA2CA4CA9 | |
| Hydrochloric Acid SCHEMBL4281770 | 0.83 | KDM4E (0.44) | KMT2A | |
| SCHEMBL4752939 | 0.81 | KMT2A (0.37) | KMT2AFAAHGAAADORA3 | |
| Hydrochloric Acid SCHEMBL4292918 | 0.81 | CYP1A2 (0.33) | RENCA1CA2CA4CA9 | |
| Hydrochloric Acid SCHEMBL4281746 | 0.81 | REN (0.33) | KMT2ARENCA1CA2CA4 | |
| SCHEMBL4288567 | 0.80 | FAAH (0.34) | KMT2AFAAHGAA | |
| Hydrochloric Acid SCHEMBL4281042 | 0.80 | SMN1; SMN2 (0.35) | FAAHREN | |
| Hydrochloric Acid SCHEMBL4284926 | 0.80 | GRN (0.36) | KMT2ARENCA1CA2CA4 | |
| SCHEMBL4297909 | 0.80 | ALDH1A1 (0.47) | KMT2ARENCA1CA2CA4 | |
| Hydrochloric Acid SCHEMBL4288220 | 0.79 | ALDH1A1 (0.46) | KMT2ARENCA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | KMT2A 1049/4885FAAH 2632/4885REN 1/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | KMT2A 1049/4885FAAH 2632/4885REN 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.